peer-OX-i-kam
Therapeutic Classification: antirheumatics, nonopioid analgesics
Pharmacologic Classification: nonsteroidal anti inflammatory drugs nsaids
Absorption: Well absorbed from the GI tract.
Distribution: Unknown. Enters breast milk in small amounts.
Half-Life: 50 hr.
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO (analgesic effect) | 1 hr | unknown | 48–72 hr |
| PO (anti-inflammatory effect) | 7–12 days | 2–3 wk‡ | unknown |
‡May take up to 12 wk.
Contraindicated in:
Use Cautiously in:
CV: edema, HF, hypertension, MI
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS
EENT: blurred vision, tinnitus
F and E: hyperkalemia
GI: discomfort, dyspepsia, nausea, vomiting, anorexia, constipation, diarrhea, flatulence, GI BLEEDING, HEPATOTOXICITY
GU: renal failure
Hemat: blood dyscrasias, prolonged bleeding time
Neuro: drowsiness, headache, dizziness, STROKE
Drug-drug:
Drug-Natural Products:
Lab Test Considerations:
NDC Code